| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Director
3 companies
Jean M. Franchi is Chief Financial Officer at REPL and has filed Form 4s across 3 companies. Jean M. Franchi's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $10.2M at current prices.
Historically, Jean M. Franchi's trades have earned a below-average insider score of 49/100 across 11 rated trades. Over a 12-month horizon, 20.0% of those trades were profitable, with an average 12-month return of -8.7%.
The biggest single holding is IRON (~$5.2M) as Chief Financial Officer. The IRON filings lean toward selling, a net 27,333 shares.
Jean M. Franchi has 31 Form 4 filings on record from December 2019 to April 2026, across 3 companies: Chief Financial Officer at Disc Medicine (IRON), 2024–2026; Biodesix (BDSX), 2021–2026; Chief Financial Officer at Replimune Group (REPL), 2019–2023.
The 50 reported transactions were 20 option or other derivative awards, 18 open-market sales, 7 stock awards and 5 option exercises.
Counted by filing, the open-market trades come to no purchases and 11 sales worth about $3.7M.
The largest open-market sale was 25,000 shares of REPL at an average $43.45 on December 14, 2020, about $1.1M.
6 of the 8 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 2 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14, 2026 | IRON Disc Medicine, Inc. | Chief Financial Officer | Sell10b5-1 | 6,657 | $69.23 | $460,834.05 | -9.4% | +7.8% | - | |
| Feb 25, 2026 | IRON Disc Medicine, Inc. | Chief Financial Officer | Sell10b5-1 | 353 | $69.06 | $24,377.09 | -0.5% | +1.9% | - | |
| Feb 18, 2026 | IRON Disc Medicine, Inc. | Chief Financial Officer | Sell10b5-1 | 11,156 | $64.51 | $719,727.16 | -13.5% | -0.6% | - | |
| Jul 17, 2025 | IRON Disc Medicine, Inc. | Chief Financial Officer | Sell10b5-1 | 2,031 | $59.00 | $119,829.00 | -3.1% | +33.2% | +27.1% | |
| Jul 10, 2025 | IRON Disc Medicine, Inc. | Chief Financial Officer | Sell10b5-1 | 2,000 | $57.50 | $115,000.00 | -3.0% | +21.2% | - | |
| Jun 16, 2025 | IRON Disc Medicine, Inc. | Chief Financial Officer | Sell10b5-1 | 2,000 | $52.26 | $104,518.80 | -2.9% | +15.1% | +34.2% | |
| Feb 18, 2025 | IRON Disc Medicine, Inc. | Chief Financial Officer | Sell | 3,136 | $54.58 | $171,162.88 | -4.3% | -9.1% | +18.0% | |
| May 16, 2023 | REPL Replimune Group, Inc. | Chief Financial Officer | Sell | 11,351 | $18.05 | $204,885.55 | -8.1% | +6.5% | -63.2% | |
| May 16, 2022 | REPL Replimune Group, Inc. | Chief Financial Officer | Sell | 3,436 | $14.59 | $50,131.24 | -3.5% | +42.1% | +27.3% | |
| Jan 14, 2021 | REPL Replimune Group, Inc. | Chief Financial Officer | Sale+OE | 15,000 | $44.53 | $667,884.00 | - | - | - |